Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice. methods Referents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year. Results Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years. Conclusions Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called ???tailored follow-up???, high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

BIGLIA, Nicoletta;
2014-01-01

Abstract

Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice. methods Referents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year. Results Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years. Conclusions Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called ???tailored follow-up???, high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.
2014
9
4 e94063
1
7
breast cancer; Follow-up; survey
C Natoli; D Brocco; I Sperduti; A Nuzzo; N Tinari; M De Tursi; A Grassadonia; L Mazzilli; S Iacobelli; T Gamucci; P Vici; Study Group; C Natoli; V Adamo; M Airoldi; D Amoroso; F Angelini; C Angiolini; G Angiolucci; A Ardizzoia; E Baldini; P Ballardini; S Barni; C Barone; N Battelli; D Bernardi; S Bianchetti; N Bianco; N Biglia; D Bilancia; G Biti; C Boni; R Bordonaro; M Botta; S Bretti; A Brunello; C Brunetti; D Bruno; E Bucci; R Buzzoni; K Cagossi; C Cappelletti; F Cappuzzo; F Cardillo; R Carroccio; S Cascinu; L Cavanna; E Cianchetti; M Clerico; A Contu; D Corsi; L Cortesi; E Cretella; S Crispino; M Di Lieto; L Di Lullo; E Durini; A Fabi; G Failla; S Fattorusso; F Ferraù; A Ferro; C Ficorella; G Fogazzi; J Foglietta; G Francini; O Fusco; A Gennari; M Ghiani; L Gianni; M Giordano; F Giotta; R Giuliani; S Gori; C Graiff; V Guarneri; D Guarneri; F Guglielmi; M Landriscina; L Laudadio; M Lombardo; F Longo; G Macellari; C Madeddu; S Magnanini; L Maiorino; A Mangiameli; G Marini; B Massidda; R Mattioli; A Michelotti; A Molino; V Montesarchio; A Morale; R Murgo; G Naso; D Natale; M Orditura; S Orrù; R Pace; A Palazzo; F Palma; A Pancotti; G Pandoli; P Papaldo; A M Parisi; R Passalacqua; A Pellegrino; B Perrucci; E Proietti; F Recchia; F Riccardi; A I Rispoli; A Rocca; I Romaniello; R Rossetti; D Rossi; G Rosti; E M Ruggeri; A Russo; A Savarino; C Savastano; G Scognamiglio; M Scognamiglio; P Seminara; S Serrachini; V Sidoti; R R Silva; G Surace; S Tomao; G Tonini; P Trenta; M Turazza; R Valenza; E Veltri; G Zampa; A Zaniboni; S Zanirato
File in questo prodotto:
File Dimensione Formato  
Breast Cancer ‘‘Tailored Follow-up’’+.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 410.72 kB
Formato Adobe PDF
410.72 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/154778
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact